Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 88 (3), 270-274
- https://doi.org/10.1016/s0002-9149(01)01639-3
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart DiseaseJAMA, 1998
- A Randomized Trial of the Effects of Atorvastatin and Niacin in Patients with Combined Hyperlipidemia or Isolated HypertriglyceridemiaAmerican Journal Of Medicine, 1998
- Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in MenCirculation, 1997
- Small LDL, Atherogenic Dyslipidemia, and the Metabolic SyndromeCirculation, 1997
- Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS)Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With HypertriglyceridemiaJAMA, 1996
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Does measurement of apolipoprotein B have a place in cholesterol management?Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.Circulation, 1990